Ares Capital Corporation (AFC) stock prices updated...
 

Ares Capital Corporation stock price

Ares Capital Corporation latest news:


  • 11/16/2017 16:19:32

    Nvidia price target boosted again at RBC

    Nvidia Corp. shares rose slightly in late trading Thursday after RBC Capital Markets analyst Mitch Steves boosted his price target on the stock. Steves moved his price target to $250 from $240 and maintained an outperform rating on the stock in a note delivered shortly after the end of Thursday's trading, explaining that the chip maker's recent earnings beat dramatically increased his best-case scenario for the stock. "Overall, after a single quarter of out-performance the 2020 upside case increases by 10%," Steves wrote. The RBC analyst had already raised his price target to $240 from $230 in the wake of Nvidia's third-quarter earnings report, along with a host of other analysts who helped push Nvidia stock to record levels. Nvidia shares gained about 0.5% in late trading after closing with a 0.8% gain at $211.61; the stock is up more than 98% so far this year, as the S&P 500 index has gained 15.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/14/2017 15:44:36

    BRIEF-Pershing Square Capital Management raises sole share stake in ADP, dissolves in Nomad Foods

    Pershing Square Capital Management: * Pershing Square Capital Management raises sole share stake in Automatic Data Processing Inc (ADP) to 8.8 million shares from 1.8 million shares - SEC Filing‍​. * Pershing Square Capital Management dissolves sole share stake in Nomad Foods (NOMD) - SEC Filing​. * Pershing Square Capital Management - change in holdings are as of Sept 30, 2017 and compared with the p...

  • 11/14/2017 14:34:02

    Achillion shares drop as J&J to sell large stake

    Achillion Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer reported promising early data on one of its kidney-disease treatments but said a large stakeholder was selling shares in a secondary offering. Achillion shares fell 9.2% to $3.35 after hours. Achillion said Johnson & Johnson Inc.'s venture capital arm, Johnson & Johnson Innovation-JJDC Inc., will sell 18.4 million shares of Achillion in a public offering and that Achillion would not receive proceeds. Achillion has 136.9 million shares outstanding. Separately, the company said early data from its mid-stage clinical trial for ACH-4471 showed the drug reduced protein in the urine by more than 50% in patients with C3 glomerulopathy, a rare disease where protein deposits build up in the kidneys.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/14/2017 12:02:58

    A rudderless Buffalo Wild Wings has a 'credible' buyer in Roark Capital

    Sports restaurant chain's shares are up some 25% Tuesday, driven there in large part by takeover talk. Stifel analysts are calling private-equity firm Roark Capital Group a "credible" potential buyer for Buffalo Wild Wings Inc. (BWLD), in part because the lengthy search for a chief executive successor reflects the restaurant chain's struggle to find its next direction. Buffalo Wild Wings (BWLD) shares soared 25% in after-hours trading on Monday after The Wall Street Journal reported that...

  • 11/14/2017 11:22:21

    Buffalo Wild Wings shares soar on report of takeover bid

    (Reuters) - Buffalo Wild Wings' shares rose nearly 26 percent in early trading on Tuesday, a day after a report said the company received a $2.3-billion takeover bid from private-equity firm Roark Capital Group.

  • 11/13/2017 16:19:06

    Buffalo Wild Wings stock soars on report of takeover offer

    Shares of Buffalo Wild Wings soar after a report that private-equity firm Roark Capital Group was offering a deal for the chicken wing chain

  • 11/13/2017 16:18:46

    Buffalo Wild Wings stock soars on report of takeover offer

    Shares of Buffalo Wild Wings soared in after-hours trading Monday after a report that private-equity firm Roark Capital Group was offering a deal for the chicken wing chain.

  • 11/13/2017 15:48:05

    BRIEF-Ra Capital Management says it purchased 850,000 shares of Kalvista Pharmaceuticals' common stock for about $7.2 ...

    Kalvista Pharmaceuticals Inc(KALV). * Ra Capital Management says ‍​on Oct 12, it purchased 850,000 shares of Kalvista Pharmaceuticals' (KALV) common stock for about $7.2 million - SEC Filing. * Ra Capital Management says it purchased the shares of Kalvista Pharmaceuticals' (KALV) common stock with its working capital Source text: [http://bit.ly/2jpXyGp] Further company coverage:

  • 11/13/2017 14:42:05

    Buffalo Wild Wings stock soars after report of acquisition bid

    Buffalo Wild Wings Inc. shares shot more than 25% higher in late trading Monday after a report that a private-equity firm had bid more than $2.3 billion for the restaurant chain. The Wall Street Journal reported that Roark Capital Group made an offer of more than $150 a share for the company in recent weeks. The stock closed Monday at $117.25, then jumped to $150 in after-hours action following the report. The franchise has been hurt by increasing prices for its core product, chicken wings, and had been targeted by activist investor Marcato Capital Management, but bounced back in the most recent quarter by switching one of its most popular promotions to boneless wings. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/13/2017 05:46:59

    Tyson shares rise after earnings and sales beat

    Tyson Foods Inc. shares rose 3.9% in Monday premarket trading after the company reported fourth-quarter earnings and sales beat estimates. Net income totaled $394.0 million, or $1.07 per share, up from $391.0 million, or $1.03 per share, for the same period last year. Adjusted EPS was $1.43, beating the $1.35 FactSet consensus. Revenue was $10.1 billion, up from $9.2 billion last year and beating the $9.9 billion FactSet estimate. Tyson brands include Jimmy Dean, Hillshire Farm, Ball Park and its namesake. The company began to divest itself of non-protein businesses during the quarter, part of an effort to focus on protein brands. And the company is integrating AdvancePierre Foods, a recent acquisition, that will provide manufacturing capabilities for sandwiches and prepared foods and increase Tyson's presence at convenience stores, according to a statement from Chief Executive Tom Hayes. The company expects $200 million in savings in fiscal 2018, fiscal year capital expenditures of $1.4 billion, and doesn't plan to repurchase shares until it a net debt of around twice EBITDA (earnings before interest, taxes, depreciation and amortization). Tyson shares are up 13.1% for the last three months, and up 20.2% for the year so far. The S&P 500 index is up 15.3% for 2017 to date.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/08/2017 11:31:38

    Capital One to cut roughly 1,000 jobs as it exits mortgage-lending business: reports

    Capital One Financial Corp. shares fell 1% in afternoon trade Wednesday, after reports that the credit card and consumer-banking services company was exiting the mortgage-loan business, cutting about 1,000 jobs. The Dallas Business Journal reported late Tuesday that Capital One was planning to lay off 950 employees from its campus in Plano, Texas in the coming months, citing a spokesperson that said the company wasn't in a position to be both competitive and profitable. Reuters reported Wednesday the company will cut about 1,100 jobs, citing a challenging interest-rate environment. The company didn't immediately respond to a request for comment. The stock has gained 2.3% year to date, while the SPDR Financial Select Sector ETF has rallied 13% and the S&P 500 has gained 16%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/08/2017 05:58:40

    UPDATE: Digital Ally shares surge 36% premarket after company puts itself up for sale

    Digital Ally Inc. shares jumped 36% in premarket trade Wednesday, after the video recording equipment and analytic software company said it is exploring its strategic alternatives including a possible sale of the company. The Lenexa, Kansas-based company said options include "monetizing its patent portfolio and related patent infringement litigation against Axon Enterprise, Inc. ("Axon," formerly known as TASER International, Inc.) and Enforcement Video, LLC d/b/a WatchGuard Video ("WatchGuard"), the sale of the company as a whole, or the sale of select properties or groups of properties or individual businesses." The company has retained Roth Capital as adviser and has already received several unsolicited inquiries involving a variety of possible deals. Shares have fallen 57% in 2017, while the S&P 500 has gained about 16%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/07/2017 15:49:08

    BRIEF-Garrison Capital Inc declares ‍net investment income of $4.2 mln

    Garrison Capital Inc(GARS): * Garrison Capital Inc(GARS) declares fourth quarter 2017 distribution of $0.28 per share and announces third quarter 2017 financial results. * Garrison Capital Inc (GARS) - ‍net investment income for quarter ended September 30, 2017 was $4.2 million, or $0.26 per share​ Source text for Eikon: Further company coverage:

  • 11/07/2017 09:06:08

    Priceline's stock plunges toward biggest-ever price decline after 'typical' downbeat guidance

    Shares of Priceline Group Inc. plunged 11% in morning trade Tuesday, and were on track to suffer their biggest-ever price decline, as investors and analysts failed to give the online travel service company a pass for its usual practice of providing downbeat earnings guidance. The stock's price decline of $210.01 is the biggest since Priceline went public in March 1999, passing the previous record of $158.06 suffered on June 24, 2016. It was on track to close below the $1,700 mark for the first time since Feb. 27, 2017. Priceline reported late Monday third-quarter earnings and revenue that beat expectations, but provided a fourth-quarter EPS outlook that was below the FactSet consensus. But that was the fourth-straight quarter that guidance was below expectations, and the 13th quarter of the past 15 quarters. RBC Capital analyst Mark Mahaney said Priceline's "conservatism" was "typical." Still, 13 of 31 analysts surveyed by FactSet cut their price targets, moving the average target down to $2.021.07 from $2,116.5 at the end of October. Priceline's stock has still gained 15.6% year to date, while the S&P 500 has climbed 15.7%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/07/2017 05:38:39

    Teva's stock, bonds fall after credit rating slashed to junk at Fitch

    Shares of Teva Pharmaceutical Industries Ltd. sank 3.6% in premarket trade Tuesday, after the Israel-based generic drug maker's credit rating was cut by two notches into "junk" territory by Fitch Ratings. Teva's most active bonds, the 3.150% notes that mature in October of 2026, fell about 3 points to 83 cents on the dollar, sending its yield up to 5.466%. The spread widened by 27 basis points to 315 basis points over comparable Treasuries. The credit rating agency said the cut in the rating, down to BB from BBB-, reflects concerns over "significant operational stress" at a time when it needs to reduce debt. "Pricing pressure in Teva's North American generics segment and erosion of sales of Copaxone will continue to weigh on free cash flow in the near term, requiring the company to continue to sell assets or find external capital resources to meed debt obligations in 2018 and 2019 and beyond," Fitch said in a statement. The rating outlook is negative. Teva's stock has plunged 66% year to date through Monday, while the SPDR S&P Pharmaceuticals ETF has gained 5.4% and the S&P 500 has climbed 16%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/06/2017 07:28:28

    Helios & Matheson is raising $100 mln in convertible notes to increase ownership in MoviePass

    Shares of MoviePass-owner Helios & Matheson Analytics Inc. were up nearly 9% in premarket trade after the data and technology company said it would raise $100 million in convertible notes in order to increase its stake in MoviePass. The conversion price of the notes is $12.06 per share. The deal will allow Helios and Matheson to pay the remaining $5 million balance the company owes MoviePass after closing its previous securities purchase agreement back in August. The financing will also be used to pay MoviePass an additional $20 million to exercise its option to increase its investment in the movie theater subscription service. Canaccord Genuity served as the sole placement agent for the financing, and Palladium Capital Advisors acted as a financial advisor to Helios and Matheson in the financing. "This investment should allow us to further augment our data science capabilities and platform to respond to the needs of studios and exhibitors and their challenges in better understanding their customers," MoviePass Chief Executive Mitch Lowe said in a statement. MoviePass recently said its subscriber base has reached 600,000; up from 20,000 before its subscription price cut back in August. Shares of Helios and Matheson are up more than 192% in the year to date, while the S&P 500 index is up close to 16% and the Dow Jones Industrial Average is up more than 19%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/27/2017 06:38:58

    Chevron shares slump premarket after earnings

    Chevron Corp. shares slid 1.2% premarket after the company reported third-quarter earnings. Chevron said it had net income of $1.952 billion, or $1.03 a share, in the quarter, up from $1.283 billion, or 68 cents a share, in the year-earlier period. Revenue rose to $36.2 billion from $30.1 billion. The FactSet consensus was for EPS of 98 cents and revenue of $34.5 billion. "Cash flow is at a positive inflection point, with oil and gas production increasing and capital spending falling," Chief Executive John Watson said in a statement. "We're completing projects that have been under construction and ramping up production, notably at our Gorgon LNG Project in Australia. And our shale and tight rock drilling activity in the Permian Basin is exceeding expectations." Shares have gained 0.6% in 2017, while the S&P 500 has gained 14%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/26/2017 12:10:29

    Stein Mart to cut 10% of its corporate office workforce

    Shares of Stein Mart Inc. slipped 0.4% in afternoon trade Thursday, after the Florida-based discount department store chain it would cut its corporate office workforce by 10%, as part of ongoing cost cutting efforts. The company expects to cuts to save about $10 million in 2018. The job cuts are in addition to previously-announced cost-cutting measures, such as the suspension of the dividend announced in May, lowering inventories by 15% and cutting capital expenditures by $22 million. "While we believe our sales-driving strategies are now taking hold, we are still in a very challenging retail environment," said Chief Executive Hunt Hawkins. The stock has plunged 78.4% year to date, while the SPDR S&P Retail ETF has slipped 7.2% and the S&P 500 has gained 14.5%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/26/2017 09:15:49

    National Vision's stock debuts 31% above its IPO price

    Shares of National Vision Holdings Inc. debuted on the Nasdaq at $28.75 at 11:05 a.m. ET, or 31% above their initial public offering price of $22. The stock was recently changing hands at $28.00, and has traded in a range of $27.66 to $29.10 since its debut. The optical retail company had priced its IPO late Wednesday, above the expected range of $18 to $20. The company offered 15.8 million shares for sale, to raise $347.6 million. National Vision plans to use the proceeds to repay debt and for general corporate purposes, which includes the payment of interest on term loans. BofA Merrill Lynch, Goldman Sachs, Citigroup and KKR Capital acted at joint bookrunning managers. National Vision has gone public at a time the SPDR S&P Retail ETF has slipped 0.4% over the past three months, while the S&P 500 has gained 3.5%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/24/2017 14:23:40

    Capital One shares rise after higher-than-expected earnings, revenue

    Shares of Capital One Financial Corp. rose late Tuesday after the company reported earnings and sales above Wall Street expectations. Capital One said it earned $1.1 billion, or $2.14 a share, in the quarter, compared with $1 billion, or $1.94 a share, in the year-ago period. Excluding one-time items, the company earned $2.42 a share in the quarter. Revenue rose 4% to $7 billion. Analysts polled by FactSet had expected Capital One to report adjusted earnings of $2.14 a share on revenue of $6.8 billion. Shares of Capital One had ended the regular trading down 0.2%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/23/2017 23:09:35

    Monte dei Paschi shares to re-list on Oct. 25

    Italy's Banca Monte dei Paschi di Siena said on Tuesday its shares would resume trading on October 25 after the market regulator approved a document for their relisting. Monte dei Paschi's shares have not traded in Milan since December 2016, when the bank failed to raise capital from investors and had to seek help from the state ahead of an 8 billion euro rescue.

  • 10/22/2017 23:40:30

    BRIEF-‍Pixium Vision establishes an equity line financing with Kepler Cheuvreux​

    PIXIUM VISION SA: * ‍PIXIUM VISION ESTABLISHES AN EQUITY LINE FINANCING WITH KEPLER CHEUVREUX​. * ‍KEPLER CHEUVREUX GAVE A FULL AND FIRM COMMITMENT TO SUBSCRIBE FOR 2,000,000 SHARES​. * ‍SHARES REPRESENT AN ISSUED CAPITAL OF EUR 6.2 M​ Source text for Eikon: Further company coverage:

  • 10/17/2017 15:09:51

    BRIEF-Viking Therapeutics files for sale of up to 6.9 mln shares by selling stockholder

    * Viking Therapeutics Inc files for sale of up to 6.9 million shares of co's common stock by selling stockholder Lincoln Park Capital Fund Llc‍‍​ - SEC filing Source text: (http://bit.ly/2x3eVPr) Further company coverage:

  • 10/17/2017 06:15:15

    Synchronoss's stock shoots up after subsidiary sale, equity investment

    Shares of Synchronoss Technologies Inc. shot up 14% in premarket trade Tuesday, after the software company announced a deal to sell a subsidiary and receive another equity investment from its largest shareholder. The company said that after completing a review of strategic alternatives, it decided to sell its wholly-owned subsidiary Intralinks Holdings Inc. to private-equity firm Siris Capital Group LLC for $1 billion. As part of the agreement, Siris will make a $185 million investment in convertible preferred equity of Synchronoss, which would be convertible into 19.8% of Synchronoss's shares outstanding. Recent filings show Siris Capital was Synchronoss's largest shareholder with a stake of 6.0 million shares, or 12.9% of the shares outstanding as of Oct. 5, according to FactSet. The deal with Siris will allow Synchronoss to focus on its core communications and media business. The stock had plunged 64% year to date through Monday, while the SPDR Technology Select Sector ETF had climbed 26% and the S&P 500 had rallied 14%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/16/2017 15:36:49

    LiveXLive seeks to raise up to $123.8 million in IPO

    LiveXLive Media Inc. plans to raise up to $123.8 million in its initial public offering, according to a Securities and Exchange Commission filing late Monday. The Beverly Hills, Calif.-based live-music video content site said will offer 7.7 million shares at $12 to 14 apiece, with underwriters getting an additional 1.2 million shares to cover overallotments. BMO Capital markets is listed as the sole book-running manager. The company plans to list with the ticker "LXL" on the New York Stock Exchange. LiveXLive reported 2016 revenue of $36.7 million and a net loss of $6.6 million, or $10.5 million to common shareholders.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/16/2017 09:17:52

    Sears' stock tumbles after CIO of large shareholder steps down from board

    Shares of Sears Holdings Corp. plunged 12% in active morning trade Monday, putting it on track to close at an 8-month low. The struggling department store chain said that Bruce Berkowitz, chief investment officer of investment advisor Fairholme Capital Management LLC, was stepping down from its board of directors at the end of the month. Fairholme Capital controlled 28.9 million Sears shares as of June 30, which would make it the second-largest shareholder with 26.9% of the shares outstanding. The stock has now erased virtually all the gains it has made since it announced a $1 billion restructuring in early February. The stock has now lost 26% over the past three months, while the SPDR S&P Retail ETF has lost 0.4% and the S&P 500 has gained 3.9%.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/13/2017 08:33:03

    OptiNose shares surge 22% in their stock market debut

    Shares of OptiNose Inc. surged more than 20% in the first ten minutes of trading on the Nasdaq Friday, as the maker of products for ear, nose and throat conditions made its stock market debut. The stock was last up $2.57, or 16%, at $18.57. OptiNose priced its initial public offering late Thursday at $16 a share, the midpoint of its $15 to $17 range, according to Renaisannce Capital, an IPO investment manager. The company, which has developed a nasal spray treatment for chronic rhinosinusitis, offered 7.5 million shares to raise $120 million, after increasing the offer from an original plan to sell 6.3 million shares. Shares are trading on the Nasdaq under the ticker symbol "OPTN." Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets were lead managers on the deal. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/13/2017 07:36:02

    OptiNose prices IPO at $16 a share, midpoint of price range

    OptiNose Inc. priced its initial public offering late Thursday at $16 a share, the midpoint of its $15 to $17 range, according to Renaisannce Capital, an IPO investment manager. The company, which has developed a nasal spray treatment for chronic rhinosinusitis, offered 7.5 million shares to raise $120 million, after increasing the offer from an original plan to sell 6.3 million shares. Shares will start trading on the Nasdaq later Friday under the ticker symbol "OPTN." Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets were lead managers on the deal. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/04/2017 14:13:49

    Immunogen shares fall after secondary share offering announced

    Immunogen Inc. shares fell in the extended session Wednesday after the biotech company announced a secondary offering of shares. Immunogen shares fell 10% to $7.05 after hours. The company said it plans to offer 13 million shares, and provide underwriters with up to 2 million shares to cover overallotments. Jefferies, Leerink Partners and RBC Capital Markets are listed as underwriters. Immunogen intends to use proceeds to finance research and development, clinical trials and for other corporate purposes. Immunogen has 115.5 million shares outstanding.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 10/03/2017 06:35:45

    Optinose to sell 6.25 million shares at $15 to $17 a pop in IPO

    Specialty pharma company Optinose on Tuesday outlined the terms of its planned initial public offering. The company, which specializes in products for ear, nose and throat and allergies, said it plans to sell 6.25 million shares priced at $15 to $17 each. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets are underwriters on the deal. The company is planning to list on the Nasdaq under the ticker symbol "OPTN." The company is planning to use the proceeds of the IPO to suppor the launch of Xhance for the treatment of chronic sinusitis, for working captial and general corporate purposes. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    Ares Capital CorporationARU | Ares Capital CorporationARY | Ares Commercial Real Estate CorporationACRE | Ares Dynamic Credit Allocation FundARDC | Ares Management L.P.ARES | Ares Multi-Strategy Credit FundARMF | ArganAGX | Arista NetworksANET | Arlington Asset Investment CorpAI | Arlington Asset Investment CorpAIC |